Log in to search using one of your social media accounts:

 

Amgen Highlights The Latest EVENITY ™ (Romosozumab) And Prolia® (Denosumab) Research At The American Society For Bone And Mineral Research Annual Meeting
First Presentation of Detailed EVENITY ARCH Study Results and FRAME Extension Final Analysis 10-Year Data From Long-Term Prolia FREEDOM Study THOUSAND OAKS, Calif., Sept. 8, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that 19 scientific abstracts will highlight the latest scientific research on EVENITY™* (romosozumab) and Prolia® (denosumab) at this year's Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) in Denver from Sept. 8-11, 2017. "The data being presented at ASBMR underscore our steadfast focus for more than a decade to advance scientific unders...
Source: Amgen News Release - September 8, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Prostate Cancer Patients Can Improve Bone Health With Osteoporosis Medications
Men with non-metastatic prostate cancer who receive androgen deprivation therapy risk loss of bone mineral density and fractures, but both bisphosphonates and denosumab can improve their bone health. (Source: CancerNetwork)
Source: CancerNetwork - August 8, 2017 Category: Cancer & Oncology Authors: Mark L. Fuerst Tags: Genitourinary Cancers News Prostate Cancer Source Type: news

Osteoporosis medications improve bone health in men being treated for prostate cancer
(American College of Physicians) Both biophosphonates and denosumab improve bone mineral density in men with nonmetastatic prostate cancer who are receiving androgen deprivation therapy. The results from a systematic review and meta-analysis are published in Annals of Internal Medicine. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 7, 2017 Category: Cancer & Oncology Source Type: news

Single Shot of Zoledronate Doesn't Preserve BMD After Denosumab Single Shot of Zoledronate Doesn't Preserve BMD After Denosumab
A single dose of zoledronate does not adequately preserve bone mineral density gains seen with long-term denosumab treatment, once the latter is discontinued.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 4, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Bone loss after denosumab, only partial protection with zoledronate
This report investigates whether a single infusion of zoledronate might also be an effective option to prevent bone loss after long-term denosumab treatment in postmenopausal patients is discontinued. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 2, 2017 Category: International Medicine & Public Health Source Type: news

Amgen Submits Supplemental Biologics License Application For Prolia ® (denosumab) In Glucocorticoid-Induced Osteoporosis
THOUSAND OAKS, Calif., July 31, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Prolia® (denosumab) for the treatment of patients with glucocorticoid-induced osteoporosis (GIOP).The sBLA is based on a Phase 3 study evaluating the safety and efficacy of Prolia compared with risedronate in patients receiving glucocorticoid treatment. Osteoporosis can be caused by glucocorticoid medications, which are prescribed to treat inflammatory diseases. Within the first three months of beginning ...
Source: Amgen News Release - July 31, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Reports Second Quarter 2017 Financial Results
THOUSAND OAKS, Calif., July 25, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2017. Key results include: Total revenues increased 2 percent versus the second quarter of 2016 to $5.8 billion. Product sales grew 2 percent driven by Prolia® (denosumab), Repatha® (evolocumab) and KYPROLIS® (carfilzomib). GAAP earnings per share (EPS) increased 18 percent to $2.91 driven by higher operating margins. GAAP operating income increased 13 percent to $2.7 billion and GAAP operating margin increased 4.9 percentage points to 48.4 percent. N...
Source: Amgen News Release - July 25, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Denosumab Shows Benefits in Multiple Myeloma Bone Disease Denosumab Shows Benefits in Multiple Myeloma Bone Disease
In a head-to-head comparison with zoledronic acid, denosumab was noninferior, with prolonged time to a first skeletal event and a reduced risk for renal events.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 27, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Amgen To Present New Data At 22nd Congress of the European Hematology Association
Oral Presentation of Phase 3 Data Shows KYPROLIS® (Carfilzomib) and Dexamethasone Improved Median Overall Survival by 7.6 Months Compared to Velcade® (Bortezomib) and Dexamethasone in Relapsed Multiple Myeloma New Subset Analysis Demonstrates BLINCYTO® (Blinatumomab) More Than Doubled Median Overall Survival Versus Standard of Care Chemotherapy in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in First Salvage Oral Presentation of New Data From Head-to-Head Phase 3 Study of XGEVA® (Denosumab) Versus Zoledronic Acid in Time to First On-Study Skeletal...
Source: Amgen News Release - June 21, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

FDA Accepts Amgen's Supplemental Biologics License Application To Expand Indication For XGEVA(R) (denosumab) To Include Multiple Myeloma Patients
FDA Sets PDUFA Target Action Date of Feb. 3, 2018 THOUSAND OAKS, Calif., June 19, 2017 -- (Healthcare Sales & Marketing Network) -- Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted the XGEVA® (denos... Biopharmaceuticals, Oncology, FDA Amgen, XGEVA, denosumab, Multiple Myeloma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 19, 2017 Category: Pharmaceuticals Source Type: news

FDA Accepts Amgen's Supplemental Biologics License Application To Expand Indication For XGEVA ® (denosumab) To Include Multiple Myeloma Patients
FDA Sets PDUFA Target Action Date of Feb. 3, 2018 THOUSAND OAKS, Calif., June 19, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted the XGEVA® (denosumab) supplemental Biologics License Application (sBLA) that seeks to expand the currently approved indication for the prevention of fractures and other skeletal-related events in patients with bone metastases from solid tumors to include patients with multiple myeloma. The FDA has set a Prescription Drug User Fee Act (PDUFA) action date of Feb. 3, 2018. "Multiple mye...
Source: Amgen News Release - June 19, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Presents New Data From Phase 3 XGEVA ® (Denosumab) Study In Patients With Multiple Myeloma At ASCO 2017
Analysis Demonstrated XGEVA had a Significantly Lower Rate of Renal Adverse Events Compared to Zoledronic Acid Data Selected for Best of ASCO® Educational Program THOUSAND OAKS, Calif., June 4, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data from the XGEVA® (denosumab) Phase 3 '482 study, the largest international multiple myeloma trial ever conducted. The study met its primary endpoint, demonstrating XGEVA is non-inferior to zoledronic acid in delaying the time to first on-study skeletal-related event in patients with multiple myeloma (HR=0.98, 95 percent CI: 0.85, 1.14; p=0.01). The ...
Source: Amgen News Release - June 4, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Comparison of osteoporosis treatments for improving bone mineral density
After teriparatide, osteoporosis treatment with denosumab yields higher additional bone mineral density gain, compared with bisphosphonates, according to data presented at the European Congress of Endocrinology 2017.Medscape (Source: Society for Endocrinology)
Source: Society for Endocrinology - May 31, 2017 Category: Endocrinology Source Type: news

Denosumab Ups BMD More Than Bisphosphates After Teriparatide Denosumab Ups BMD More Than Bisphosphates After Teriparatide
Use of denosumab after stopping teriparatide yields a greater increase in bone-mineral density in postmenopausal women with severe osteoporosis than bisphosphonates, according to a retrospective analysis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 25, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Amgen Highlights Data To Be Presented At ASCO 2017 Across Oncology Portfolio
Oral Presentation of New Analysis on Limited Renal Toxicity Associated With XGEVA® (denosumab) Compared With Zoledronic Acid in Treatment of Myeloma Bone Disease XGEVA Study in Patients With Myeloma Bone Disease Also Selected for Best of ASCO® First Randomized Study to Evaluate the Combination of IMLYGIC® (talimogene laherparepvec), an Oncolytic Viral Immunotherapy, With a Checkpoint Inhibitor to be Presented THOUSAND OAKS, Calif., May 17, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new clinical data and analyses from across its oncology portfolio will be presented at the 53rd An...
Source: Amgen News Release - May 17, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Medical News Today: Osteoporosis: ACP update treatment guidelines for preventing bone fractures
In revised guidelines, the ACP strongly advise that women with osteoporosis should be treated with bisphosphonates or denosumab to prevent bone fractures. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 9, 2017 Category: Consumer Health News Tags: Bones / Orthopedics Source Type: news

ACP Updates Guidelines on Treating Low Bone Density, Osteoporosis (FREE)
By Amy Orciari Herman Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD Clinicians should offer alendronate, risedronate, zoledronic acid, or denosumab to women with osteoporosis to reduce the risk for hip and vertebral fractures (strong … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - May 9, 2017 Category: Primary Care Source Type: news

Guideline for treating low bone density or osteoporosis to prevent fractures
The American College of Physicians recommends in an evidence-based clinical practice guideline that physicians treat women with osteoporosis with bisphosphonates (alendronate, risedronate, or zoledronic acid) or denosumab, a biologic agent. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - May 8, 2017 Category: Science Source Type: news

Reassuring Long-term Safety Trends With Denosumab Treatment Reassuring Long-term Safety Trends With Denosumab Treatment
There appear to be no worsening safety trends when denosumab is used long term for the treatment of osteoporosis in postmenopausal women, according to the seven-year FREEDOM Extension trial.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - April 20, 2017 Category: Orthopaedics Tags: Rheumatology News Source Type: news

Osteoporosis drug found safe for postmenopausal women in long-term trial
A new clinical trial has shown the short- and long-term safety of the drug denosumab to treat postmenopausal osteoporosis. (Source: Health News - UPI.com)
Source: Health News - UPI.com - April 7, 2017 Category: Consumer Health News Source Type: news

Amgen Submits Applications In The US And Europe To Expand Current Indication For XGEVA ® (denosumab) To Include Patients With Multiple Myeloma
XGEVA is Currently Indicated for the Prevention of Skeletal-Related Events Known as Bone Complications in Patients With Solid Tumors Applications Include Data From the Largest International Trial Conducted in Multiple Myeloma THOUSAND OAKS, Calif., April 4, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) and an application for a variation to the marketing authorization to the European Medicines Agency (EMA) for XGEVA® (denosumab). The submissions to regulatory authorities seek to exp...
Source: Amgen News Release - April 4, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Osteoporosis drug found safe in long-term trial
A new study provides reassuring information about the short-term and long-term safety of denosumab, a monoclonal antibody that is used to treat postmenopausal osteoporosis. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - March 17, 2017 Category: Science Source Type: news

Study finds osteoporosis drug safe in long-term trial
Researchers have determined the osteoporosis drug denosumab is safe and effective at treating osteoporosis and preventing bone fractures. (Source: Health News - UPI.com)
Source: Health News - UPI.com - March 17, 2017 Category: Consumer Health News Source Type: news

Osteoporosis drug found safe in long-term trial
(Wiley) A new study provides reassuring information about the short-term and long-term safety of denosumab, a monoclonal antibody that is used to treat postmenopausal osteoporosis. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 17, 2017 Category: Global & Universal Source Type: news

Amgen Presents New Data From Phase 3 XGEVA ® (denosumab) Study In Multiple Myeloma Patients At The 16th International Myeloma Workshop
In this study, XGEVA® (denosumab) met the primary endpoint, demonstrating non-inferiority to zoledronic acid in delaying the time to first on-study skeletal-related event (SRE) in patients with multiple myeloma (HR=0.98, 95 percent CI: 0.85, 1.... (Source: Amgen News Release)
Source: Amgen News Release - March 3, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen To Present New KYPROLIS ® (Carfilzomib) And XGEVA® (Denosumab) Data At The 16th International Myeloma Workshop
Detailed Results From Phase 3 Head-to-Head ENDEAVOR Trial Show KYPROLIS Significantly Improved Overall Survival Compared to Velcade® (Bortezomib) in Relapsed or Refractory Multiple Myeloma Patients Late-Breaking Results From Largest International Trial Conducted in Multiple Myeloma Show XGEVA was Non-Inferior Versus Zoledronic Acid in Delaying Bone Complications THOUSAND OAKS, Calif., March 1, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new data from the KYPROLIS® (carfilzomib) and XGEVA® (denosumab) clinical development programs will be presented at the 16th International Myeloma ...
Source: Amgen News Release - March 1, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Bone Loss Resumes When Long-term Denosumab Therapy Stops Bone Loss Resumes When Long-term Denosumab Therapy Stops
Bone loss resumes during the year following discontinuation of long-term denosumab therapy, although it is attenuated in patients who begin another osteoporosis therapy.Reuters Health Information (Source: Medscape Orthopaedics Headlines)
Source: Medscape Orthopaedics Headlines - February 15, 2017 Category: Orthopaedics Tags: Diabetes & Endocrinology News Source Type: news

Amgen Reports Fourth Quarter And Full Year 2016 Financial Results
THOUSAND OAKS, Calif., Feb. 2, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the fourth quarter and full year of 2016. Key results include: For the fourth quarter, total revenues increased 8 percent versus the fourth quarter of 2015 to $6.0 billion. Product sales grew 6 percent driven by Enbrel® (etanercept), Prolia® (denosumab), Repatha® (evolocumab) and KYPROLIS® (carfilzomib). For the full year, total revenues increased 6 percent to $23.0 billion, with 5 percent product sales growth. GAAP earnings per share (EPS) increased 9 percent in the fourth ...
Source: Amgen News Release - February 2, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Data To Be Presented At ACR/ARHP 2016 Annual Meeting Show Amgen's Ongoing Commitment To Therapies For Patients With Serious Inflammatory And Bone Diseases
21 Abstracts to be Featured Provide Real-World and Disease State Insights, Highlight Clinical and Health Economic Impact of Rheumatologic Diseases and Osteoporosis THOUSAND OAKS, Calif., Nov. 7, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will present data from multiple studies related to Enbrel® (etanercept), Prolia® (denosumab) and AMJEVITA™ (adalimumab-atto), as well as investigational candidates, including ABP 710 (infliximab biosimilar candidate) and romosozumab, at the American College of Rheumatology (ACR) and Association of Rheumatology Health Professionals (ARHP) Annual...
Source: Amgen News Release - November 7, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Xgeva May Boost Bone Erosion Repair in RA (CME/CE)
(MedPage Today) -- Denosumab/DMARD combination should be considered (Source: MedPage Today Geriatrics)
Source: MedPage Today Geriatrics - October 31, 2016 Category: Geriatrics Source Type: news

FRAME: Romosozumab Rapidly Reduces Fracture Risk in Osteoporosis FRAME: Romosozumab Rapidly Reduces Fracture Risk in Osteoporosis
Romosozumab rapidly and dramatically reduces vertebral fractures compared with placebo in FRAME, and bone-enhancing effects continue after patients are transitioned to denosumab for a further year.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 19, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Results From Phase 3 FRAME Study Of Romosozumab Showed Significant Reductions In Both New Vertebral And Clinical Fractures In Postmenopausal Women With Osteoporosis
FRAME Data Simultaneously Published in New England Journal of Medicine and Presented at ASBMR Showed Treatment With Romosozumab Significantly Reduced New Vertebral and Clinical Fractures Through 12 Months Significant Bone Mineral Density Gains Shown at Six and 12 Months at the Lumbar Spine, Total Hip and Femoral Neck Bone Mineral Density Continued to Increase and Vertebral Fracture Risk Reduction Persisted With the Transition From Romosozumab to Denosumab Through 24 Months THOUSAND OAKS, Calif. and BRUSSELS, Sept. 18, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and UCB (Euronext Brussels: UCB) today announced f...
Source: Amgen News Release - September 18, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen to Highlight 19 Abstracts on Osteoporosis Disease State and Treatment at American Society for Bone and Mineral Research Annual Meeting
Results From Phase 3 FRAME Study of Romosozumab Evaluate Fracture Risk Reduction in Women With Postmenopausal Osteoporosis Real-World and Clinical Data Focus on Long-Term Efficacy and Safety of Prolia® (Denosumab), Provide Insights on Therapy Compliance in Patients With Postmenopausal Osteoporosis THOUSAND OAKS, Calif., Sept. 7, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will present data from multiple studies for its investigational agent romosozumab and for Prolia® (denosumab) at the Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) in Atlanta on Sept. ...
Source: Amgen News Release - September 17, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Announces Positive Top-Line Results From Phase 3 Study Of Prolia ® (Denosumab) In Patients Receiving Glucocorticoid Therapy
Study Indicates That Prolia Led to Greater Gains in Bone Mineral Density at 12 Months Compared With Risedronate in Patients Receiving Glucocorticoid Therapy THOUSAND OAKS, Calif., Aug. 29, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced positive top-line results from the primary analysis conducted in a Phase 3 randomized, double-blind, double-dummy, active-controlled study evaluating the safety and efficacy of Prolia® (denosumab) compared with risedronate in patients receiving glucocorticoid treatment. The study met all primary and secondary endpoints at 12 months. The data showed that treatment wit...
Source: Amgen News Release - September 17, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen to Highlight 19 Abstracts on Osteoporosis Disease State and Treatment at American Society for Bone and Mineral Research Annual Meeting
Results From Phase 3 FRAME Study of Romosozumab Evaluate Fracture Risk Reduction in Women With Postmenopausal Osteoporosis Real-World and Clinical Data Focus on Long-Term Efficacy and Safety of Prolia® (Denosumab), Provide Insights on Therapy Compliance in Patients With Postmenopausal Osteoporosis THOUSAND OAKS, Calif., Sept. 7, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that it will present data from multiple studies for its investigational agent romosozumab and for Prolia® (denosumab) at the Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) in Atlanta on Sept. ...
Source: Amgen News Release - September 7, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Prolia (Denosumab Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 30, 2016 Category: Drugs & Pharmacology Source Type: news

Xgeva (Denosumab) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 30, 2016 Category: Drugs & Pharmacology Source Type: news

Amgen Announces Positive Top-Line Results From Phase 3 Study Of Prolia ® (Denosumab) In Patients Receiving Glucocorticoid Therapy
Study Indicates That Prolia Led to Greater Gains in Bone Mineral Density at 12 Months Compared With Risedronate in Patients Receiving Glucocorticoid Therapy THOUSAND OAKS, Calif., Aug. 29, 2016 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced positive top-line results from the primary analysis conducted in a Phase 3 randomized, double-blind, double-dummy, active-controlled study evaluating the safety and efficacy of Prolia® (denosumab) compared with risedronate in patients receiving glucocorticoid treatment. The study met all primary and secondary endpoints at 12 months. The data showed that treatment wit...
Source: Amgen News Release - August 29, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Reports Second Quarter 2016 Financial Results
THOUSAND OAKS, Calif., July 27, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2016. Key results include: Revenues increased 6 percent versus the second quarter of 2015 to $5.7 billion. Product sales grew 5 percent driven by Enbrel® (etanercept), Prolia® (denosumab), KYPROLIS® (carfilzomib) and XGEVA® (denosumab). GAAP earnings per share (EPS) increased 15 percent to $2.47 driven by higher revenues and higher operating margins. GAAP operating income increased 15 percent to $2,380 million and GAAP operating margin improved by 3.8...
Source: Amgen News Release - July 27, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Medical News Today: Breast cancer: Existing drug shows promise for prevention in high-risk women
An existing drug called denosumab has shown promise for the delay or prevention of breast cancer among women with a BRCA1 mutation. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 21, 2016 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Breast cancer cell growth halted by osteoporosis drug, study shows
A trial in mice has shown that the drug denosumab could become a preventative breast cancer treatment for women with BRCA1 gene mutationsWomen who have a high risk of breast cancer may benefit from a drug that is already prescribed to treat bone loss in old age, according to scientists in Australia.Researchers found that the osteoporosis drug, denosumab, can halt the growth of cells which give rise to breast tumours in women whose risk of the disease is greater because of mutations in a gene called BRCA1. Continue reading... (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - June 20, 2016 Category: Science Authors: Ian Sample Science editor Tags: Genetics Science Breast cancer Ovarian cancer Health Society Medical research Biology Source Type: news

Scientists reveal drug that prevents Angelina Jolie breast cancer gene could be step closer
Denosumab may have potential to prevent breast cancer from developing in women with BRCA1 gene, scientists from The Walter and Eliza Hall Institute, Australia found. (Source: the Mail online | Health)
Source: the Mail online | Health - June 20, 2016 Category: Consumer Health News Source Type: news

Amgen's First Quarter 2016 Revenues Increased 10 Percent To $5.5 Billion And Adjusted Earnings Per Share (EPS) Increased 17 Percent To $2.90
First Quarter 2016 GAAP EPS Were $2.50 2016 Total Revenues and Adjusted EPS Guidance Increased to $22.2-$22.6 Billion and $10.85-$11.20, Respectively THOUSAND OAKS, Calif., April 28, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2016. Key results include: Total revenues increased 10 percent versus the first quarter of 2015 to $5,527 million, with 7 percent product sales growth driven by Enbrel® (etanercept), Prolia® (denosumab), Aranesp® (darbepoetin alfa), Neulasta® (pegfilgrastim), Kyprolis® (carfilzomib) and XGEVA® (denosumab). A...
Source: Amgen News Release - April 28, 2016 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Combo Therapy vs Monotherapy for Postmenopausal OsteoporosisCombo Therapy vs Monotherapy for Postmenopausal Osteoporosis
The combination of denosumab and teriparatide improves bone microarchitecture and estimated strength more than either drug alone in women with severe postmenopausal osteoporosis, researchers have found. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 23, 2016 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news